| Name | Carisbamate |
| Description | Carisbamate (RWJ-333369) is an orally active neuromodulator that suppresses the development and propagation of epileptiform discharges, confers neuroprotection following epilepticus-like injury in vitro, and demonstrates robust antiepileptic efficacy in genetic models of generalized and nonconvulsive epilepsy, supporting its translational relevance in epilepsy research. |
| In vitro | In cultured hippocampal neurons, Carisbamate (200 μM) acutely inhibited spontaneous recurrent epileptiform discharges (SREDs) after 12 hours in over 95% of neurons, with effects maintained for 24 hours [1]. |
| In vivo | In the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model, intraperitoneal (i.p.) administration of Carisbamate (10, 30, 60 mg/kg) reduced the expression of spike-and-wave discharges (SWD) dose-dependently. The 60 mg/kg dose completely inhibited SWD after 120 minutes. In audiogenic sensitive Wistar AS rats, Carisbamate (20, 30 mg/kg, i.p.) prevented wild running episodes and tonic seizures in all animals. At 10 mg/kg, the latency to tonic seizure was increased by 327% [6]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (371.01 mM), Sonication is recommended.
|
| Keywords | JNJ 10234094 | Carisbamate |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Dibucaine |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max |
United States
